Previous 10 | Next 10 |
Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 7, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu , President and CEO, and Dr. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech company Vaxart (NASDAQ: VXRT ) is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When I first wrote about Vaxart (NASDAQ: VXRT ) stock on Aug. 10, I was completely enamored by the clinical-stage biotech company’s attempts to bring an oral Covid-19 vaccine to the market. Source: Asca...
Penny Stocks To Buy For Less Than A Cup Of Coffee; Are They Worth It? What are penny stocks? According to the basic Securities & Exchange Commission definition, these are stocks that can be bought for under $5 a share. When you’re talking about low prices, there are a few thi...
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors Dr. Cherrington brings decades of research and development experience and executive leadership to Vaxart's Board PR Newswire SOUTH SAN FRANCISCO, Calif. , A...
Vaxart Announces Creation of New Scientific and Clinical Advisory Board Leaders in Health Care, Vaccines, and Academic Research to Advise Vaxart as it Progresses Its Ground-Breaking Technology PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 19, 2021 /PRNewswir...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips “The pill that moves the needle.” This is the statement highlighted on Vaxart’s (NASDAQ: VXRT ) website, and it is written to make a bold impression. Recently, the company has been in the spotligh...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) announced it is now proceeding to a Phase-2 clinical trial for its oral Covid-19 vaccine (a pill instead of a shot) in its Aug. 5 earnings release for the quarter ending June 30. This gives bo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’m privileged today to be talking about the California-based biotech Vaxart (NASDAQ: VXRT ) stock. I’ve never written about the company, but I find the idea of oral recombinant vaccines to be a compe...
Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings ...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...